Method of treating c3 glomerulopathy
Patent Information
- Authority / Receiving Office
- US · United States
- Current Assignee / Owner
- CHEMOCENTRYX INC
- Publication Date
- 2017-07-20
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is an application claiming priority benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 278,788 filed Jan. 14, 2016; U.S. Provisional Application No. 62 / 280,346 filed Jan. 19, 2016; U.S. Provisional Application No. 62 / 347,450 filed Jun. 8, 2016; and U.S. Provisional Application No. 62 / 397,527 filed Sep. 21, 2016, each of which is herein incorporated by reference in its entirety for all purposes.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0002] Not ApplicableREFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK
[0003] Not ApplicableBACKGROUND OF THE INVENTION
[0004] C3 glomerulopathy (C3G) is a rare disease of the kidney (the prevalence of C3G is estimated at 2-3 per 1,000,000 people). C3G is characterized by deposition of the protein known as C3 (a component of the body's complement system) in the filtr...